Ming Poi

1.7k total citations
64 papers, 1.2k citations indexed

About

Ming Poi is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Ming Poi has authored 64 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Molecular Biology, 31 papers in Oncology and 16 papers in Hematology. Recurrent topics in Ming Poi's work include Cancer-related Molecular Pathways (12 papers), Multiple Myeloma Research and Treatments (11 papers) and Protein Kinase Regulation and GTPase Signaling (6 papers). Ming Poi is often cited by papers focused on Cancer-related Molecular Pathways (12 papers), Multiple Myeloma Research and Treatments (11 papers) and Protein Kinase Regulation and GTPase Signaling (6 papers). Ming Poi collaborates with scholars based in United States, India and Taiwan. Ming Poi's co-authors include Junan Li, Ming‐Daw Tsai, Mitch A. Phelps, In‐Ja L. Byeon, Daqing Wang, Wolfgang Sadée, Andrea Gaedigk, Xiaochun Sun, J. Steven Leeder and Craig C. Hofmeister and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Molecular Biology.

In The Last Decade

Ming Poi

64 papers receiving 1.2k citations

Peers

Countries citing papers authored by Ming Poi

Since Specialization

Citations

This map shows the geographic impact of Ming Poi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ming Poi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ming Poi more than expected).

Fields of papers citing papers by Ming Poi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ming Poi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ming Poi. The network helps show where Ming Poi may publish in the future.

Co-authorship network of co-authors of Ming Poi

This figure shows the co-authorship network connecting the top 25 collaborators of Ming Poi. A scholar is included among the top collaborators of Ming Poi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ming Poi. Ming Poi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Multidimensional Analysis of B7 Homolog 3 RNA Expression in Small Cell Lung Cancer Molecular Subtypes 2025 ·Clinical Cancer Research ·Carl M. Gay, Taofeek K. Owonikoko, Lauren A. Byers, Noura J. Choudhury, (unknown), Zachary Cain, Xiaozhong Qian, Matthew Brentnall, Simon Heeke, Ming Poi, (unknown), Charles M. Rudin	1
2	CYP3A5 influences oral tacrolimus pharmacokinetics and timing of acute kidney injury following allogeneic hematopoietic stem cell transplantation 2024 ·Frontiers in Pharmacology ·Nathan D. Seligson, Xunjie Zhang, (unknown), (unknown), Zachary VanGundy, Daqing Wang, Mitch A. Phelps, Julianna Roddy, Craig C. Hofmeister, Junan Li, Ming Poi	2
3	A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies 2021 ·Cancer Chemotherapy and Pharmacology ·Katharine A. Collier, (unknown), Herbert B. Newton, Erinn M. Hade, Douglas W. Sborov, Robert Cavaliere, Ming Poi, Mitch A. Phelps, (unknown), Christopher C. Coss, (unknown), (unknown), Paul Monk, Charles L. Shapiro, Richard Piekarz, Craig C. Hofmeister, D. Bradley Welling, Amir Mortazavi	20
4	Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer 2021 ·Gynecologic Oncology ·Floor Backes, Lai Wei, Min Chen, Kasey Hill, (unknown), Ming Poi, Mitch A. Phelps, Ritu Salani, Larry J. Copeland, Jeffrey M. Fowler, David E. Cohn, Kristin Bixel, Casey Cosgrove, John L. Hays, David M. O’Malley	13
5	Cisplatin Induced the Expression ofSEI1(TRIP-Br1) Oncogene in Human Oral Squamous Cancer Cell Lines 2019 ·Anticancer Research ·Junan Li, Zachary VanGundy, Ming Poi	1
6	A Single Nucleotide Polymorphism in SLC7A5 Was Associated With Clinical Response in Multiple Myeloma Patients 2018 ·Anticancer Research ·Ming Poi, Junan Li, (unknown), (unknown), Douglas W. Sborov, Mitch A. Phelps, Craig C. Hofmeister	11
7	Deletion of RDINK4/ARF enhancer: A novel mutation to “inactivate” the INK4-ARF locus 2017 ·DNA repair ·Ming Poi, Thomas J. Knobloch, Junan Li	7
8	Polymorphism in ANRIL is associated with relapse in patients with multiple myeloma after autologous stem cell transplant 2017 ·Molecular Carcinogenesis ·Ming Poi, Junan Li, Douglas W. Sborov, Zachary VanGundy, (unknown), (unknown), Flavia Pichiorri, Mitch A. Phelps, Craig C. Hofmeister	28
9	A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy 2016 ·Annals of Hematology ·Farrukh T. Awan, Jeffrey A. Jones, Kami J. Maddocks, Ming Poi, Michael R. Grever, Amy J. Johnson, John C. Byrd, Leslie A. Andritsos	34
10	Erlotinib in African Americans With Advanced Non–Small Cell Lung Cancer: A Prospective Randomized Study With Genetic and Pharmacokinetic Analyses 2014 ·Clinical Pharmacology & Therapeutics ·Mitch A. Phelps, Thomas E. Stinchcombe, James S. Blachly, Weiqiang Zhao, Larry J. Schaaf, (unknown), Lai Wei, Ming Poi, Daqing Wang, András Papp, Josephine Aimiuwu, Yue Gao, J. Li, Gregory A. Otterson, William J. Hicks, Mark A. Socinski, Miguel A. Villalona‐Calero	18
11	A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol 2013 ·Clinical Cancer Research ·Jia Ji, Diane R. Mould, Kristie A. Blum, Amy S. Ruppert, Ming Poi, Yuan Zhao, Amy J. Johnson, John C. Byrd, Michael R. Grever, Mitch A. Phelps	19
12	Standard Pentostatin Dose Reductions in Renal Insufficiency Are Not Adequate: Selected Patients with Steroid-Refractory Acute Graft-Versus-Host Disease 2013 ·Clinical Pharmacokinetics ·Ming Poi, Craig C. Hofmeister, Jeffrey S. Johnston, Ryan B. Edwards, (unknown), David Lucas, Sherif S. Farag, James T. Dalton, Steven M. Devine, Michael R. Grever, Mitch A. Phelps	3
13	Evidence that P12, a specific variant of P16INK4A, plays a suppressive role in human pancreatic carcinogenesis 2013 ·Biochemical and Biophysical Research Communications ·Ming Poi, Thomas J. Knobloch, Chunhua Yuan, Ming‐Daw Tsai, Christopher M. Weghorst, Junan Li	10
14	Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review 2013 ·Supportive Care in Cancer ·Ming Poi, Michael Berger, Maryam B. Lustberg, Rachel M. Layman, Charles L. Shapiro, Bhuvaneswari Ramaswamy, Ewa Mrózek, Erin M. Olson, Robert Wesolowski	29
15	A phase I trial of flavopiridol in relapsed multiple myeloma 2013 ·Cancer Chemotherapy and Pharmacology ·Craig C. Hofmeister, Ming Poi, (unknown), Weiqiang Zhao, Mitch A. Phelps, Don M. Benson, Eric H. Kraut, Sherif S. Farag, Yvonne A. Efebera, Jennifer Sexton, Thomas S. Lin, Michael R. Grever, John C. Byrd	32
16	Regulatory Mechanisms of Tumor Suppressor P16^INK4Aand Their Relevance to Cancer 2011 ·Biochemistry ·Junan Li, Ming Poi, Ming‐Daw Tsai	247
17	Suggestive evidence for the involvement of the second calcium and surface loop in interfacial binding: monoclinic and trigonal crystal structures of a quadruple mutant of phospholipase A₂ 2006 ·Acta Crystallographica Section D Biological Crystallography ·K. Sekar, M. Yogavel, Shankar Prasad Kanaujia, (unknown), D. Velmurugan, Ming Poi, Zbigniew Dauter, Ming‐Daw Tsai	4
18	Atomic resolution (0.97 Å) structure of the triple mutant (K53,56,121M) of bovine pancreatic phospholipase A₂ 2004 ·Acta Crystallographica Section F Structural Biology and Crystallization Communications ·K. Sekar, V. Rajakannan, D. Gayathri, D. Velmurugan, Ming Poi, Mirosława Dauter, Zbigniew Dauter, Ming‐Daw Tsai	2
19	Observation of Additional Calcium Ion in the Crystal Structure of the Triple Mutant K56,120,121M of Bovine Pancreatic Phospholipase A2 2002 ·Journal of Molecular Biology ·V. Rajakannan, M. Yogavel, Ming Poi, A. Arockia Jeyaprakash, Jeyaraman Jeyakanthan, D. Velmurugan, Ming‐Daw Tsai, K. Sekar	15
20	SomaticINK4a-ARF locus mutations: A significant mechanism of gene inactivation in squamous cell carcinomas of the head and neck 2001 ·Molecular Carcinogenesis ·Ming Poi, (unknown), Junan Li, Huijuan Song, Jas C. Lang, David E. Schuller, Dennis K. Pearl, Bruce C. Casto, Ming‐Daw Tsai, Christopher M. Weghorst	42

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact